- Home
- RCS vs HRTX Comparison
RCS vs HRTX Comparison
Compare RCS & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.39
Company Overview
Basic Information| Metric | RCS | HRTX |
|---|---|---|
| Founded | 1994 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.6M | 265.9M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | RCS | HRTX |
|---|---|---|
| Price | $6.00 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 141.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $155,097,000.00 |
| Revenue This Year | N/A | $8.98 |
| Revenue Next Year | N/A | $11.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.60 |
| 52 Week Low | $4.51 | $1.00 |
| 52 Week High | $6.31 | $2.68 |
Technical Indicators
Market Signals| Indicator | RCS | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 50.27 |
| Support Level | $5.75 | $1.45 |
| Resistance Level | $6.15 | $1.42 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 57.14 | 28.57 |
Price Performance
Historical Comparison RCS
HRTX
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.